» Articles » PMID: 32176003

Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants

Overview
Date 2020 Mar 17
PMID 32176003
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Kaposiform hemangioendothelioma is an aggressive vascular tumor with infiltrative growth that commonly occurs in infancy and is associated with a life-threatening consumptive coagulopathy, as well as Kasabach-Merritt phenomenon. Recently, promising results have shown that sirolimus had been successfully used to treat Kasabach-Merritt phenomenon without significant toxicity. However, the situation the authors encountered in treating infants was not so satisfactory. Here, the authors present 2 patients younger than 3 months with refractory Kaposiform hemangioendothelioma treated with sirolimus and experienced severe pneumonia. The outcomes suggest that it is necessary to keep an eye on any symptoms indicate the infection of respiratory tract and use the antibiotics in time. The 2 cases also remind us of the potential sign that indicate the recurrence of KMP, which refers to firmer lesion with deepen color, especially when it comes with complications.

Citing Articles

Sirolimus for vascular anomalies in the first year of life: a systematic review.

Cavazos R, Patil M, Gowda S, Iacobas I, Rosenberg T, Fernandes C J Perinatol. 2024; 44(8):1087-1097.

PMID: 38245657 DOI: 10.1038/s41372-024-01868-9.


Efficacy of transcatheter arterial chemoembolization combined with sirolimus for treating Kasabach-Merritt phenomenon in infants, a retrospective study.

Yin C, Qi W, Wang S, Pan D, Chen X, Li S Ann Med. 2023; 55(1):2196090.

PMID: 37038342 PMC: 10101661. DOI: 10.1080/07853890.2023.2196090.


Case report: Kaposi hemangioendothelioma of the right upper limb with the Kasabach-Merritt phenomenon: A potentially lethal diagnostic challenge.

Belani L, Sapuan J, Abdullah S, Yee Hing E, Loh C, Alias H Front Pediatr. 2022; 10:995399.

PMID: 36389350 PMC: 9664933. DOI: 10.3389/fped.2022.995399.


Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.

Harbers V, van der Salm N, Pegge S, van der Vleuten C, Verhoeven B, Vrancken S Br J Clin Pharmacol. 2021; 88(6):2769-2781.

PMID: 34957601 PMC: 9303919. DOI: 10.1111/bcp.15202.


[Clinical features of Kasabach-Merritt syndrome: an analysis of 16 neonates].

Wang Y, Dai L, Wang L, Zhang J, Wang S, Zuo W Zhongguo Dang Dai Er Ke Za Zhi. 2021; 23(7):696-701.

PMID: 34266526 PMC: 8292658.